Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.
about
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisEfficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trialsReview: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aDevelopment of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course.Oligoarticular and polyarticular JIA: epidemiology and pathogenesis.Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritisRandomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent.Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis.Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis.Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.Treatment advances in systemic juvenile idiopathic arthritis.Judicious use of biologicals in juvenile idiopathic arthritis.Canakinumab for the treatment of systemic juvenile idiopathic arthritis.New frontiers in the treatment of systemic juvenile idiopathic arthritis.Pain intensity variability and its relationship with quality of life in youths with juvenile idiopathic arthritis.[Still's disease in children and adults].Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort.Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.Review: Genetics and the Classification of Arthritis in Adults and Children.Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.Atopy in children with systemic onset juvenile idiopathic arthritis (SoJIA) is associated with a worse outcome.IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis.The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.Disease-specific regulation of gene expression in a comparative analysis of juvenile idiopathic arthritis and inflammatory bowel disease.
P2860
Q24610145-62DFF356-A9C3-4405-B8D9-F7254923C48BQ26775512-D3193280-1C1D-4EFE-9431-5FEB81039FC1Q27002805-EA82F131-25E0-42AF-910B-D44C83343DF5Q33613293-F0BE05ED-0094-4214-9399-76CD153A73F4Q34023067-E5792AC2-AB0D-40DE-A193-2BB29F0DCEEFQ34158894-1AF67A65-5EEA-47F9-9CCB-819F82176F6BQ34268714-A08D74A3-E363-4600-B980-07799F2BF610Q34269827-86F48C6B-4D1F-4ED8-BA62-FCEF68C5FCF9Q34455674-41E12A3F-4691-4DCB-BDBA-F1128F87945DQ35041117-AF8C8F37-3D41-476B-AC82-CD267C9494A8Q35567870-1254CCEB-3752-47E0-A706-5B79796D5A86Q36183846-398E1DB7-5697-4A65-B1E7-2D969C7DEA45Q36435446-868D3363-9B09-4B00-9724-176CF42F7CD4Q36453159-B49F95C2-7542-4E52-BC33-8EF81BA0F1A6Q37451624-52A24554-AF0E-4310-9845-60541AF3E421Q37602644-C30E7D8E-F6E6-499D-B38F-3581DE9C8B3CQ37747792-A8CAE3E5-2B23-41B1-AD9D-10F9E17A37EAQ38044757-2ECE5230-A25B-4A17-9337-681A74D63A94Q38161412-13AD9294-47CC-4016-ACF5-C89E9C8529EEQ38176004-EF2A0FDA-67D4-44EF-8128-26ED6A153FB2Q38207061-75A25238-0638-4196-B5EC-21D06E5D7050Q38248905-D8DC4B36-3CEA-4E74-AB3C-CA1D0896881FQ38255582-D5621978-276D-4FAC-BB37-6050DB5F7E8AQ39424746-A19CC601-8B4B-49DF-A2C3-8EB41C09A4A6Q39553765-78556380-D53A-4D46-812D-2AFB573D0F16Q40045645-5BA97A66-2792-4C31-8B90-8477C15294FBQ40335671-415F118D-1DB8-4092-A74E-3814ACB3F2A1Q41731211-52CD9B53-9BA3-47C0-A44D-3C5AA2135C96Q43689633-66CD5E5B-467A-4FA7-8C5E-EBD620B934D8Q47150341-67279FF5-8CE5-4456-A95D-0199EBCD3CCDQ47811289-320105DB-BCBE-4AD7-8C97-EEF93DD79616Q48514200-D3DBE5C1-9A57-41E5-8E7E-E85B8A0CBF3EQ51155090-879AFA8F-A781-4080-B2D5-EE206F868A12Q52330721-00036FFF-630E-4BA1-981C-C43742FEA36AQ54945619-85CFB633-24E9-4464-B573-C076AF8B3C1EQ55206915-60BACE71-569C-4171-8D02-29A324291DC6Q55513036-15A45C85-DC18-4474-832A-4E196FB5A5B6
P2860
Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Predictors of disease course a ...... nical and laboratory features.
@ast
Predictors of disease course a ...... nical and laboratory features.
@en
Predictors of disease course a ...... nical and laboratory features.
@nl
type
label
Predictors of disease course a ...... nical and laboratory features.
@ast
Predictors of disease course a ...... nical and laboratory features.
@en
Predictors of disease course a ...... nical and laboratory features.
@nl
prefLabel
Predictors of disease course a ...... nical and laboratory features.
@ast
Predictors of disease course a ...... nical and laboratory features.
@en
Predictors of disease course a ...... nical and laboratory features.
@nl
P2093
P356
P1476
Predictors of disease course a ...... nical and laboratory features.
@en
P2093
Feldman BM
Schneider R
Singh-Grewal D
P304
P356
10.1002/ART.21774
P577
2006-05-01T00:00:00Z